Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 6;9(2):102.
doi: 10.3390/pathogens9020102.

Effect and Analysis of Bacterial Lysates for the Treatment of Recurrent Urinary Tract Infections in Adults

Ricardo E Ahumada-Cota  1 , Ulises Hernandez-Chiñas  2   3 , Feliciano Milián-Suazo  4 , María E Chávez-Berrocal  2   3 , Armando Navarro-Ocaña  3 , Daniel Martínez-Gómez  5 , Genaro Patiño-López  6 , Erika P Salazar-Jiménez  2 , Carlos A Eslava  2   3
Affiliations

Effect and Analysis of Bacterial Lysates for the Treatment of Recurrent Urinary Tract Infections in Adults

Ricardo E Ahumada-Cota et al. Pathogens. .

Abstract

Urinary tract infection (UTI) is a relevant public health problem, economically and socially affecting the lives of patients. The increase of antimicrobial bacterial resistance significantly hinders the treatment of UTIs, raising the need to search for alternative therapies. Bacterial lysates (BL) obtained from Escherichia coli and other pathogens have been used to treat different infectious diseases with promising results. This work aims to evaluate the effect and composition of an autologous BL for the treatment and control of recurrent UTIs in adults. The results show remission in 70% of the patients within the first three months after the administration of BL, while the infection is maintained under control for 6-12 months. The analysis by liquid chromatography-mass spectrometry (LC-MS) of the BL fractions recognized by the sera of patients shows the presence of cytosolic proteins, fimbriae, OMPs, and LPS. Our study demonstrates that the autologous BL contributed to the treatment and control of recurrent UTIs in adults, and its composition shows that different surface components of E. coli are potential immunogens that could be used to create a polyvalent protective vaccine.

Keywords: bacterial lysates; recurrent UTI; uropathogenic E. coli.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Sera reactivity to the BLs. ELISA assay for the evaluation of the sera reactivity of patients pre- and post-treatment and donors with no UTIs (Healthy) to the 4 BLs of the most frequent isolated serogroups (O75, O25, O6, and O8) and control strains (CFT073 and HB101).
Figure 2
Figure 2
Sera reactivity to BL fractions. Western-Blot analysis of the BLs fractions resolved in a 12% SDS-PAGE, transferred to a PVDF membrane and incubated with the sera of patients (a) post-treatment and (b) donors with no UTIs. MW: molecular weight marker; lanes 1-6: O75 BL, O25 BL, O6 BL, O8 BL, CFT073 BL, and HB101 BL, respectively. Highly immunogenic fractions with post-treatment and donor sera are inside the white square.
Figure 3
Figure 3
Western blot test. Sera reactivity to OMPs. The OMP enriched extract from (a) E. coli O75 was resolved in a 12% SDS-PAGE stained with Coomassie blue. Proteins were transferred to a PVDF membrane and incubated with the sera of (b) post and (c) pre-treatment patients and (d) donors with no UTIs. OMPs between 30 and 37 kDa are inside the white square. Protein fractions marked with an asterisk were sent for sequencing and are listed in Table S2.
Figure 4
Figure 4
Western blot test. Sera reactivity to E. coli surface structures. The bacterial surface structures extracts were resolved in (a) 12% SDS-PAGE stained with Coomassie blue. The proteins were transferred to a PVDF membrane and incubated with the sera of (b) post-treatment patients and (c) donors with no UTIs. MW: molecular weight marker; lanes 1–5: CFT073 BL, O75 BL, O6 BL, O8 BL, and HB101 BL, respectively. Protein fractions marked with an asterisk were sent for sequencing and are listed in Table S2.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Flores-Mireles A.L., Walker J.N., Caparon M., Hultgren S.J. Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 2015;13:269–284. doi: 10.1038/nrmicro3432. - DOI - PMC - PubMed
    1. Foxman B. Urinary tract infection syndromes: Occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect. Dis. Clin. N. Am. 2014;28:1–13. doi: 10.1016/j.idc.2013.09.003. - DOI - PubMed
    1. Foxman B. The epidemiology of urinary tract infection. Nat. Rev. Urol. 2010;7:653–660. doi: 10.1038/nrurol.2010.190. - DOI - PubMed
    1. O’Brien V.P., Hannan T.J., Nielsen H.V., Hultgren S.J. Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections. Microbiol. Spectr. 2016;4 doi: 10.1128/microbiolspec.UTI-0013-2012. - DOI - PMC - PubMed
    1. Ochoa S.A., Cruz-Córdova A., Luna-Pineda V.M., Reyes-Grajeda J.P., Cázares-Domínguez V., Escalona G., Sepúlveda-González M.E., López-Montiel F., Arellano-Galindo J., López-Martínez B., et al. Multidrug- and Extensively Drug-Resistant Uropathogenic Escherichia coli Clinical Strains: Phylogenetic Groups Widely Associated with Integrons Maintain High Genetic Diversity. Front. Microbiol. 2016;7:2042. doi: 10.3389/fmicb.2016.02042. - DOI - PMC - PubMed

LinkOut - more resources